Dexmedetomidine and Fentanyl Versus Midazolam and Remifentanil for Sedation in Patients Undergoing Ablation Procedures
Status:
Terminated
Trial end date:
2019-05-14
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of dexmedetomidine and compare this to a current
technique commonly used at TGH for sedation in patients undergoing ablation procedures for
atrial fibrillation (AF) and atrial flutter.
The investigators hypothesise that dexmedetomidine will be at least equivalent to, or more
so, in terms of effectiveness and safety, when compared to midazolam and remifentanil for
sedation during ablation procedures.